Physician profile
Robert Patrick Daze
NPI 1326535741
$9,780.24
in general payments reported to CMS, 2019-2025
34 companies · $2,957 in 2025
The $2,957 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $97.26 · 2021: $198 · 2022: $940 · 2023: $2,214 · 2024: $3,135 · 2025: $2,957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,754 · Education: $552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,753.99 |
| Education | $551.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,013.95 | 2020-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,125.42 | 2023-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $995.64 | 2021-2025 | Ilumya |
| Pfizer INC. | $780.83 | 2022-2025 | |
| Lilly USA, LLC | $515.87 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $481.06 | 2023-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $480.36 | 2023-2025 | Nemluvio, Aklief |
| Journey Medical Corporation | $467.42 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $464.61 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $412.06 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $399.56 | 2022-2025 | Opzelura |
| Genentech USA, INC. | $255.58 | 2019-2020 | |
| Leo Pharma INC. | $252.42 | 2023-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $202.39 | 2024-2025 | |
| Amgen INC. | $187.14 | 2023-2024 | Otezla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $111.10 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $105.77 | 2022-2025 | |
| Kerecis Limited | $57.95 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Celgene Corporation | $53.94 | 2024 | Sotyktu |
| Organon LLC | $46.92 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $42.42 | 2022 | |
| Mallinckrodt Hospital Products INC. | $41.85 | 2024-2025 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $37.28 | 2023-2025 | Siliq, Jublia |
| Botanix Sb INC | $33.84 | 2025 | Sofdra |
| Lnhc, INC | $28.57 | 2025 | Zelsuvmi |
| Helsinn Therapeutics (U.S.), INC. | $27.75 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.24 | 2022 | |
| Verrica Pharmaceuticals INC. | $26.18 | 2025 | Ycanth |
| Merz North America, INC. | $22.02 | 2022 | |
| Almirall LLC | $18.98 | 2022 | |
| Biofrontera INC. | $18.73 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $17.11 | 2020 | |
| Mayne Pharma Commercial LLC | $15.92 | 2025 | |
| Arcutis Biotherapeutics, INC. | $13.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Daze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.